88 results
424B5
ATHE
Alterity Therapeutics Ltd
15 Feb 24
Prospectus supplement for primary offering
5:28pm
capability would materially impair our ability to successfully market and sell our pharmaceutical products.
If healthcare insurers and other … subsidiaries may develop and market may be later withdrawn from the market or subject to promotional limitations.
Healthcare reform measures and other
F-3
ATHE
Alterity Therapeutics Ltd
2 Oct 23
Shelf registration (foreign)
8:44am
would materially impair our ability to successfully market and sell our pharmaceutical products.
If healthcare insurers and other organisations do … may develop and market may be later withdrawn from the market or subject to promotional limitations.
Healthcare reform measures and other statutory
6-K
EX-99.1
ATHE
Alterity Therapeutics Ltd
31 Aug 23
Report of Foreign Private Issuer
12:58pm
ability to successfully market and sell our pharmaceutical products.
If healthcare insurers and other organisations do not pay for our products … be later withdrawn from the market or subject to promotional limitations.
Healthcare reform measures and other statutory or regulatory changes could
6-K
EX-99.1
ATHE
Alterity Therapeutics Ltd
31 Aug 23
Report of Foreign Private Issuer
10:11am
as Company
Medicine / Healthcare / Research
– other
MBA
AICD Member, Graduate or Fellow
Directorships (current and previous)
Gender
Industry – same
6-K
EX-99.1
4vles5jp4m8xf d0
31 Aug 22
Report of Foreign Private Issuer
2:08pm
6-K
EX-99.1
k8pegxbph068l3rwyk9
31 Aug 22
Report of Foreign Private Issuer
11:54am
6-K
EX-99.1
h3b4vx
22 Jul 22
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
6:02am
6-K
EX-99.1
4oc0o gmihye9w
14 Jun 22
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
6:02am
6-K
EX-99.1
ceqiwbvgypwqrm
26 May 22
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
6:05am
6-K
EX-99.1
xwxxl
2 May 22
Appendix 4C – Q3 FY22 Quarterly Cash Flow Report
6:35am
6-K
EX-99.1
odx1i
27 Apr 22
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
6:04am
6-K
EX-99.1
0dirse8
27 Jan 22
Appendix 4C – Q2 FY22 Quarterly Cash Flow
6:06am
6-K
EX-99.1
hsxg81w1ppjs
3 Sep 21
Report of Foreign Private Issuer
6:15am
6-K
EX-99.1
6skhmvs 9n3zxa0
29 Apr 21
Appendix 4C – Q3 FY21 Quarterly Cash Flow Report
6:04am
6-K
EX-99.1
0vw32ur6
10 Mar 21
Alterity CEO Dr David Stamler presents to US investors at Authorization & Additional information
6:19am
6-K
EX-99.1
ca6b7
11 Jan 21
Alterity participates in world’s largest virtual healthcare conference JP Morgan
6:25am
6-K
xek35oe6zvvys 2l
11 Jan 21
Alterity participates in world’s largest virtual healthcare conference JP Morgan
6:25am